I last covered Alexion Pharmaceuticals (ALXN) in October 2018. Since then, much has changed for the pharmaceutical industry as well as the company. Despite the rise in headwinds, I continue to believe in Alexion Pharmaceuticals' growth story. In fact, I believe that this can be an optimal entry point for retail investors to pick up this rare disease player.
Let us see why Alexion Pharmaceuticals is an attractive pick in February 2020.
Alexion Pharmaceuticals continues to post impressive financial performance
In the fourth quarter, Alexion Pharmaceuticals' revenues rose YoY (year over year) by 22.63%